The escalating global burden of antimicrobial resistance (AMR) represents a critical public health challenge. This rise in antibiotic resistance is concomitant with heightened antibiotic consumption, with an estimated annual usage of 100,000 to 200,000 tons. A recent systematic review, which analysed data from 204 countries, reported that AMR was responsible for 4.95 million deaths in 2019 (Murray et al., 2022). The growing threat of AMR is imposing a significant financial burden on the global economy, with the CDC reporting an additional annual cost of $20 billion in the U.S. and €9 billion in Europe. The emerging field of bacteriophage therapy offers promising potential as a game-changer in the era of AMR. However, existing literature reveals numerous research gaps and technological challenges, including insufficient information on phage pharmacology, genomics, and a lack of preclinical and clinical data. In addition to conducting further research to address existing knowledge gaps, establishing phage banks in clinical facilities could be a transformative advancement in the fight against AMR.

中文翻译：

---

彻底改变感染控制：构建下一代噬菌体库


不断加剧的全球抗微生物药物耐药性 （AMR） 负担是一项严峻的公共卫生挑战。抗生素耐药性的增加伴随着抗生素消费量的增加，估计每年的使用量为 100,000 至 200,000 吨。最近的一项系统评价分析了来自 204 个国家的数据，报告称 2019 年抗微生物药物耐药性造成 495 万人死亡（Murray 等人，2022 年）。日益增长的 AMR 威胁给全球经济带来了沉重的财务负担，CDC 报告称，美国每年额外增加 200 亿美元，欧洲每年额外增加 90 亿欧元。噬菌体疗法的新兴领域具有广阔的潜力，有望成为 AMR 时代的游戏规则改变者。然而，现有文献揭示了许多研究空白和技术挑战，包括噬菌体药理学、基因组学信息不足以及缺乏临床前和临床数据。除了进行进一步研究以解决现有的知识差距外，在临床设施中建立噬菌体库可能是对抗 AMR 的变革性进步。